Cryo Cell International Inc (CCEL)
| Market Cap | $37.33M+14.0% |
| Revenue (ttm) | $31.13M |
| Net Income | -$1.95M |
| EPS | -$0.24 |
| Shares Out | 8.06M |
| PE Ratio | n/a |
| Forward PE | 231.50 |
| Dividend | $0.60(0.00%) |
| Ex-Dividend Date | May 21, 2025 |
| Volume | 18,952 |
| Open | $4.52 |
| Previous Close | $4.55 |
| Day's Range | $4.18 - $4.75 |
| 52-Week Range | $2.72 - $5.45 |
| Beta | 0.55 |
| Analysts | none |
| Price Target | n/a |
| Earnings Date | n/a |
About CCEL
Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States. The company offers cellular processing and cryogenic storage for family use, primarily for collection and preservation of umbilical cord blood, and tissue stem cells; and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. It is also involved in the manufacturing of PrepaCyte CB processing system units for processing umbilical cord blood stem cells. In addition, the company provides cold storage services to third-party pharmaceutical companies and medical institutions. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. The company was incorporated in 1989 and is headquartered in Oldsmar, Florida.
$CCEL stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in CCEL holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CCEL's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CCEL Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New CCEL patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CCEL from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from CCEL’s recent data — informational, not investment advice
